Abstract
SARS-CoV-2 has been reported as a possible triggering factor for the development of several autoimmune diseases and inflammatory dysregulation. Here, we present a case report of a woman with a history of systemic lupus erythematosus and antiphospholipid syndrome, presenting with concurrent COVID-19 infection and immune thrombotic thrombocytopenic purpura (TTP). The patient was treated with plasma exchange, steroids, and caplacizumab with initial good response to therapy. The course of both TTP and COVID-19 disease was mild. However, after ADAMTS-13 activity was normalized, the patient experienced an early unexpected TTP relapse manifested by intravascular hemolysis with stable platelet counts requiring further treatment. Only 3 cases of COVID-19 associated TTP were reported in the literature thus far. We summarize the literature and suggest that COVID-19 could act as a trigger for TTP, with good outcomes if recognized and treated early.
References
1.
Hindilerden
F
, Yonal-Hindilerden
I
, Akar
E
, Kart-Yasar
K
. Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: report of a case
. Thromb Res
. 2020 Jul 5
;195
:136
–8
.2.
Albiol
N
, Awol
R
, Martino
R
. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19
. Ann Hematol
. 2020
;99
(7
):1673
–4
. .3.
Capecchi
M
, Mocellin
C
, Abbruzzese
C
, Mancini
I
, Prati
D
, Peyvandi
F
. Dramatic presentation of acquired TTP associated with COVID-19
. Haematologica
. 2020 Jul 2
;105
:e540
–1
.4.
Porta
C
, Caporali
R
, Montecucco
C
. Autoimmunity in thrombotic thrombocytopenic purpura
. Semin Thromb Hemost
. 2005
;31
(6
):633
–40
. .5.
Fayyaz
A
, Igoe
A
, Kurien
BT
, Danda
D
, James
JA
, Stafford
HA
, Haematological manifestations of lupus
. Lupus Sci Med
. 2015 Mar 3
;2
(1
):e000078
. .6.
Jin
M
, Casper
TC
, Cataland
SR
, Kennedy
MS
, Lin
S
, Li
YJ
, Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
. Br J Haematol
. 2008
;141
(5
):651
–8
. .7.
Goshua
G
, Pine
AB
, Meizlish
ML
, Chang
CH
, Zhang
H
, Bahel
P
, Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
. Lancet Haematol
. 2020
;7
(8
):e575
–82
. .8.
Bazzan
M
, Montaruli
B
, Sciascia
S
, Cosseddu
D
, Norbiato
C
, Roccatello
D
. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients
. Intern Emerg Med
. 2020
;15
(5
):861
–3
. .9.
Escher
R
, Breakey
N
, Lämmle
B
. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients
. Thromb Res
. 2020
;192
:174
–5
. .10.
Zakarija
A
, Kwaan
HC
, Moake
JL
, Bandarenko
N
, Pandey
DK
, McKoy
JM
, Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008)
. Kidney Int Suppl
. 2009
(112
):S20
–4
. .11.
Zakarija
A
, Bandarenko
N
, Pandey
DK
, Auerbach
A
, Raisch
DW
, Kim
B
, Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration
. Stroke
. 2004
;35
(2
):533
–7
. .12.
Scully
M
, Cataland
SR
, Peyvandi
F
, Coppo
P
, Knöbl
P
, Kremer Hovinga
JA
, Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
. N Engl J Med
. 2019
;380
(4
):335
–46
. .14.
Behtaj
M
, Zhu
ML
, Bittencourt
CE
, Ha
JP
, Maitta
RW
. Non-O blood group thrombotic thrombocytopenic purpura patients take longer to recover as measured by number of therapeutic plasma exchanges needed for platelet recovery
. Thromb Res
. 2020 Jan
;185
:78
–84
. .15.
Goel
R
, Tobian
AAR
, Shaz
BH
. Noninfectious transfusion-associated adverse events and their mitigation strategies
. Blood
. 2019
;133
(17
):1831
–9
. .16.
Hendrickson
JE
, Tormey
CA
. Understanding red blood cell alloimmunization triggers
. Hematology Am Soc Hematol Educ Program
. 2016
;2016
(1
):446
–51
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
